- About Allist
- R & D
On April 10, 2021, 2021 China Pharmaceutical Innovation 100 Summit themed “Rise of Medicine in China: Innovators Coming Together” took place in Shanghai. The Summit witnessed the founding of “China Pharmaceutical Innovation 100 Union” (CPIU100) that was jointly initiated by Healthcare Executive Magazine, innovative drug companies, traditional medicine companies that have gone through transformation and upgrading, and R&D companies dedicated to medicine innovation in China. As a founding member of the Union’s council, Ms. Sandy Mu, CEO of Allist, attended the event marking the establishment of CPIU100.
Ms. Sandy Mu, CEO of Allist, attended the founding event of CPIU100 (5th from the left, first row)
With uncompromised dedication to innovation, CPIU100 is poised to serve as a sustainable platform for the in-depth exchange of high-level insights and experiences. Upholding the concept of innovation of excellence, it seeks to pool wisdom, build consensus, and overcome the innovation barrier, in a bid to support the sound development of innovative pharmaceutical businesses in China. Devoted to creating a better ecology for innovation, CPIU100 commits itself to the promotion of the high-quality development of the pharmaceutical industry in China, and the provision of ongoing opportunities of exchange and cooperation for innovative drug companies across the country.